Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple MyelomaBruno Paiva, Noemí Puig, María‐Teresa Cedena et al.|Journal of Clinical Oncology|2019Cited by 279
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myelomaCristina Pérez, Bruno Paiva, Cirino Botta et al.|Blood|2020Cited by 156
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple MyelomaJuan‐José Garcés, Bruno Paiva, María‐Teresa Cedena et al.|Journal of Clinical Oncology|2022Cited by 114
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myelomaLaura Rosiñol, Joan Bladé, Albert Oriol et al.|Blood|2023Cited by 62
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenanceMaría‐Victoria Mateos, Jesús F. San Miguel, Norma C. Gutiérrez et al.|Blood|2011Cited by 58